BioGaia AB (publ) BIOG-B.ST
Nasdaq Stockholm · Healthcare · Drug Manufacturers - Specialty & Generic
122.10 SEK
+1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for BioGaia
| SEK million | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | – | 1,104 | 1,297 | 1,423 | 1,538 |
| EBITDA | – | 477 | 495 | 475 | 452 |
| Net income | – | 374 | 365 | 351 | 333 |
| Balance sheet | |||||
| Equity | – | 1,972 | 2,030 | 1,724 | 1,314 |
| Total debt | 10 | – | – | – | – |
| Cash | – | 1,488 | 1,544 | 1,224 | 801 |
| Net debt | – | – | – | – | – |
| Ratios and per share | |||||
| EBITDA margin | – | 43.2% | 38.2% | 33.4% | 29.4% |
| Profit margin | – | 33.9% | 28.2% | 24.7% | 21.6% |
| Return on equity | – | 19.0% | 18.0% | 20.4% | 25.3% |
| Earnings/share (SEK) | – | 3.70 | 3.62 | 3.47 | 3.29 |
| Book value/share (SEK) | – | 19.53 | 20.11 | 17.04 | 12.99 |
| Shares outstanding (M) | – | 101 | 101 | 101 | 101 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 37.1 |
| P/B | 9.4 |
| EV / EBITDA | 25.6 |
| Net debt / EBITDA | −1.8 |
| Return on equity | 25.3% |
| Profit margin | 21.6% |
| Beta 1Y | 0.30 |
| Revenue growth 1Y | +8.1% |
| Revenue CAGR 3Y | +11.7% |
| Earnings/share CAGR 3Y | −3.9% |
| ROE avg. 3Y | 21.2% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 4.00 |
| 2025 | 6.90 |
| 2024 | 6.90 |
| 2023 | 2.90 |
| 2022 | 2.98 |
Not investment advice. Figures may contain errors from the data source.